BE645302A - - Google Patents
Info
- Publication number
- BE645302A BE645302A BE645302DA BE645302A BE 645302 A BE645302 A BE 645302A BE 645302D A BE645302D A BE 645302DA BE 645302 A BE645302 A BE 645302A
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US145432A US3149036A (en) | 1961-10-16 | 1961-10-16 | Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent |
Publications (1)
Publication Number | Publication Date |
---|---|
BE645302A true BE645302A (xx) | 1964-09-17 |
Family
ID=22513085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE645302D BE645302A (xx) | 1961-10-16 | 1964-03-17 |
Country Status (2)
Country | Link |
---|---|
US (1) | US3149036A (xx) |
BE (1) | BE645302A (xx) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1015251A (en) * | 1963-03-12 | 1965-12-31 | Glaxo Lab Ltd | Aqueous pharmaceutical compositions in capsule form |
GB1171125A (en) * | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US3531565A (en) * | 1969-09-25 | 1970-09-29 | American Cyanamid Co | Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acid |
US3678149A (en) * | 1970-01-26 | 1972-07-18 | Samuel J Prigal | Method of enhancing the action of a medicament |
US4158054A (en) * | 1973-10-18 | 1979-06-12 | Duncan Flockhart & Co. Ltd. | Preparation of virus sub-unit vaccines |
US4069313A (en) * | 1974-11-19 | 1978-01-17 | Merck & Co., Inc. | Water-in-oil adjuvant composition |
US4053584A (en) * | 1975-02-12 | 1977-10-11 | Recherche Et Industrie Therapeutiques | Pre-farrowing pregnant sow piglet colibacillosis vaccines and process for their administration to pregnant sows before farrowing |
US4073743A (en) * | 1975-04-17 | 1978-02-14 | Merck & Co., Inc. | Process for preparing an emulsion |
JPS5289612A (en) * | 1976-01-22 | 1977-07-27 | Iwao Hishida | Granular composite of metallic soap |
US4104403A (en) * | 1976-12-21 | 1978-08-01 | Witco Chemical Corporation | Water-oil emulsions and method of preparing same |
US4167560A (en) * | 1977-04-12 | 1979-09-11 | Texas Vet Lab, Inc. | Polyvalent shipping fever vaccine |
EP0009277B1 (en) * | 1978-09-14 | 1984-04-18 | Gist-Brocades N.V. | Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains |
NL7812359A (nl) * | 1978-12-20 | 1980-06-24 | Gist Brocades Nv | Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins. |
US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
NL8301996A (nl) * | 1983-06-06 | 1985-01-02 | Duphar Int Res | Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins. |
US4556556A (en) * | 1984-03-23 | 1985-12-03 | Advanced Genetics Research Institute | Vaccine for the prevention of vesicular stomatitis virus infection |
US4981685A (en) * | 1986-03-07 | 1991-01-01 | Utah State University Foundation | Bacterial extract vaccines for veterinary application |
US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
IE921212A1 (en) * | 1991-04-19 | 1992-10-21 | Affinity Biotech Inc | Convertible microemulsion formulations |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US20010055581A1 (en) * | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
JP2008504216A (ja) * | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
AU2005209318B2 (en) * | 2004-01-28 | 2010-02-11 | Cytimmune Sciences, Inc. | Functionalized colloidal metal compositions and methods |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
EP2219458B1 (en) * | 2007-11-08 | 2015-07-15 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
US8425922B2 (en) * | 2009-01-05 | 2013-04-23 | EpitoGenesis, Inc. | Adjuvant compositions and methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB888180A (xx) * | 1900-01-01 | |||
US1791878A (en) * | 1926-05-17 | 1931-02-10 | Strauch Clauss Burkart | Water-oil emulsion and suspension for medical purposes and process for manufacturing the same |
US2055083A (en) * | 1932-07-13 | 1936-09-22 | Winthrop Chem Co Inc | Pharmaceutical preparation |
US2154432A (en) * | 1936-04-27 | 1939-04-18 | J C Shay Inc | Therapeutic colloid |
US2529461A (en) * | 1949-04-30 | 1950-11-07 | Sharp & Dohme Inc | Emulsions |
US2675343A (en) * | 1951-12-18 | 1954-04-13 | Smith Kline French Lab | Emulsion-forming liquid product |
US2819199A (en) * | 1953-10-27 | 1958-01-07 | Schenley Lab Inc | Stable injectable fat emulsions and process of producing same |
GB759577A (en) * | 1953-12-17 | 1956-10-17 | Bristol Lab Inc | Oral therapeutic preparations containing coconut oil |
US2988484A (en) * | 1956-07-24 | 1961-06-13 | Drew & Co Inc E F | Alcohol soluble pharmaceutical compositions |
US3083142A (en) * | 1958-02-27 | 1963-03-26 | Glaxo Group Ltd | Improved swine erysipelas vaccine |
US2981658A (en) * | 1958-07-07 | 1961-04-25 | Julius S Youngner | Lipid purification and concentration of viruses and vaccines therefrom |
US2972565A (en) * | 1958-04-04 | 1961-02-21 | Univ Tennessee Res Corp | Fat composition |
US3099601A (en) * | 1959-10-02 | 1963-07-30 | Anchor Serum Company | Bacterin in aqueous polyethylene, mineral oil emulsion |
US3096249A (en) * | 1960-05-10 | 1963-07-02 | Samuel J Prigal | Emulsion composition |
-
1961
- 1961-10-16 US US145432A patent/US3149036A/en not_active Expired - Lifetime
-
1964
- 1964-03-17 BE BE645302D patent/BE645302A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US3149036A (en) | 1964-09-15 |